Skip to main content

Table 1 Patient baseline characteristics

From: Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

Characteristics First-line Second-line All patients (%)
   No (%) No (%)   
Sex Male 12 (100) 20 (100) 32 (100)
  Female 0 (0) 0 (0) 0 (0.0)
Age, median   58 (45-70) 66 (54-76) 60.5(45~76)
ECOG PS 0 3 (25) 6 (30) 9 (28.1)
  1 9 (75) 13 (65) 22 (68.8)
  2 0 (0) 1 (5) 1 (3.1)
Histology Squamous 12 (100) 20 (100) 32 (100)
Smoking history Never 0 (0) 2 (10) 2 (6.3)
  Ever 12 (100) 18 (90) 30 (93.7)
Prior therapy None 6 (50) N/A   6  
  Surgery 6 (50) 4 (20) 10  
  Radiation 0 (0) 2 (10) 2  
  Chemotherapy N/A   20 (100) 20  
No.of metastatic sites 1 3 (25.0) 5 (25) 8 (25.0)
  2 3 (25.0) 10 (50) 13 (40.6)
  3 1 (8.3) 4 (20) 5 (15.6)
Locoregional   5 (41.7) 1 (5) 6 (18.8)
Metastatic   7 (58.3) 19 (95) 26 (81.3)
Liver   3 (25.0) 13 (65) 16 (50.0)
Lung   7 (58.3) 19 (95) 26 (81.3)
Bone   2 (16.7) 5 (25) 7 (21.9)
  1. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; N/A, Not applicable.